argenx SE (ARGX) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown
ARGX's revenue distribution by segment and geography
By Geography
ARGX Revenue Analysis (2013–2024)
As of March 2, 2026, argenx SE (ARGX) generated trailing twelve-month (TTM) revenue of $3.95 billion, reflecting solid growth of +5.1% year-over-year. The most recent quarter (Q2 2025) recorded $948.0 million in revenue, down 29.6% sequentially.
Looking at the longer-term picture, ARGX's 5-year compound annual growth rate (CAGR) stands at +94.6%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $2.19 billion in 2024, representing a new all-time high.
When compared to Healthcare sector peers including CANF (-16.0% YoY), ABVX (+125.1% YoY), and KYMR (-16.7% YoY), ARGX has underperformed the peer group in terms of revenue growth. Compare ARGX vs CANF →
Peer Comparison
Compare ARGX's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ARGXCurrent | $4.0B | +5.1% | +94.6% | -1.0% | |
| CANF | $674,000 | -16.0% | -19.8% | -1206.2% | |
| ABVX | $11M | +125.1% | +457.7% | -1602.9% | |
| KYMR | $39M | -16.7% | +2.9% | -891.3% | |
| TGTX | $329M | +31.0% | +364.6% | 12.7% | |
| KNSA | $678M | +60.1% | - | 11.4% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $2.19B | +78.6% | $1.96B | 89.6% | $-21,654,000 | -1.0% |
| 2023 | $1.23B | +198.6% | $1.11B | 90.4% | $-425,049,000 | -34.7% |
| 2022 | $410.7M | -17.4% | $381.3M | 92.8% | $-720,341,000 | -175.4% |
| 2021 | $497.3M | +1105.7% | $497.3M | 100.0% | $-348,746,000 | -70.1% |
| 2020 | $41.2M | -47.4% | $41.2M | 100.0% | $-477,617,000 | -1158.1% |
| 2019 | $78.5M | +219.3% | $78.5M | 100.0% | $-198,892,000 | -253.5% |
| 2018 | $24.6M | -43.8% | $24.6M | 100.0% | $-93,627,000 | -381.0% |
| 2017 | $43.7M | +182.3% | $43.7M | 100.0% | $-27,512,000 | -63.0% |
| 2016 | $15.5M | +106.5% | $15.5M | 100.0% | $-22,523,000 | -145.6% |
| 2015 | $7.5M | +64.1% | $7.5M | 100.0% | $-17,061,000 | -227.7% |
See ARGX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARGX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ARGX vs AGIO
See how ARGX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ARGX's revenue growth accelerating or slowing?
ARGX maintains +5.1% revenue growth, in line with its 5-year CAGR of +94.6%. TTM revenue stands at $4.0B. Growth rate remains consistent with historical average.
What is ARGX's long-term revenue growth rate?
argenx SE's 5-year revenue CAGR of +94.6% reflects the sustained expansion pattern. Current YoY growth of +5.1% is near this long-term average.
How is ARGX's revenue distributed by segment?
ARGX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.